Knight Therapeutics Named No. 40 on Quebec's Top Growing Companies With 53% Revenue Growth

Knight Therapeutics Inc. was named No. 40 on the 2026 Report on Business magazine ranking of Quebec's Top Growing Companies, with three-year revenue growth of 53%. The Montreal-based pharmaceutical company announced the ranking in a GlobeNewswire release on November 13, 2026.

Knight's Place on Quebec's First Growth Ranking

Knight Therapeutics acquires, in-licenses and commercializes pharmaceutical products for Canada and Latin America, operating through subsidiaries United Medical, Biotoscana Farma and Laboratorio LKM. Quebec's Top Growing Companies is an editorial ranking launched in 2026 within Report on Business magazine's Canada's Top Growing Companies portfolio, recognizing industry leaders in select provinces.

"We are honored to be named one of Quebec's Top Growing Companies, a recognition that is especially meaningful for a company founded in Montreal," said Samira Sakhia, President and CEO of Knight. "Our 53% three-year revenue growth reflects the stellar performance of our business development team adding more products to our pipeline and portfolio, as well as the focused execution by our regulatory, quality, medical and commercial teams in getting these products approved, launched, reimbursed and prescribed."

Sakhia said the company has more than 50 product launches still ahead and looks forward to bringing new treatment options to patients across Canada and Latin America. Garth Thomas, Managing Director of The Globe and Mail, Business and Financial Products, said the regional ranking brings "new energy, focus, and perspective to the diverse range of businesses and success stories across the country." The full list of 2026 winners is published on The Globe and Mail Report on Business magazine website.

Knight's Revenue and Deal Record

Knight reported full-year 2025 revenue of $450 million, exceeding guidance of $430-440 million, and guided to $510-525 million for FY 2026, according to akta.pro company records. The same records show Q1 2026 revenues of $148.4 million, a 69% year-over-year increase, and adjusted EBITDA of $27.9 million, up 130% year-over-year. Knight's total funding stands at $528.5 million, with its last round a $38.5 million post-IPO debt facility in December 2022 led by International Finance Corporation.

Approvals and Launches Before the Ranking

On November 5, 2026, Knight reported third-quarter revenues of $137.7 million, up 13% year-over-year, and a net loss of $2.7 million, raising its 2026 revenue guidance to $560-570 million, according to Business & Financial. On October 6, 2026, the company announced ANVISA's expedited rare disease approval of NIKTIMVO (axatilimab) in Brazil for chronic graft-versus-host disease and the launch of TAVALISSE in Brazil for adults with chronic immune thrombocytopenia, Financial Post reported. On September 25, 2026, Knight placed No. 345 on The Globe and Mail's eighth annual ranking of Canada's Top Growing Companies, also with three-year revenue growth of 53%, Financial Post reported.

Tavalisse's Planned Colombia Launch

Knight expects to launch Tavalisse in Colombia in the first half of 2027, following approvals in Mexico and Brazil, AInvest reported on September 1, 2026.